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1 GENERAL PART 
1.1 Introduction 
1.1.1 New Psychoactive Substances (NPS) 
The phenomenon of New Psychoactive Substances (NPS) has increased attention 
over the last past years. NPS were sold over the internet under terms such as “bath 
salts”, “research chemicals”, “plant food” or “legal highs” and were primarily 
synthesized to avoid law enforcements [1, 2]. Most of these substances were not 
basically new; they were previously described in the (scientific) literature some years 
ago. For example, Alexander Shulgin synthesized and tested 179 phenethylamines 
and 55 tryptamines and published the results of his self-testing in his books “Pikhal 
(Phenethylamines I have known and loved)” in 1991 and “Tikhal (Tryptamines I have 
known and loved)” in 1995 [3, 4]. However, there are also compounds synthesized by 
university laboratories or pharmaceutical companies for development of new drugs. 
One example is 4-methyl-amphetamine (4-MA) that has been designed and 
synthesized in the 1950s as Aptrol®, an appetite suppressant, but was never released. 
It was then rediscovered around 2010 when the first seizures were reported. It seems 
that formerly published data about drugs with the desired effects were consulted before 
starting to synthesize them in high scale and sell.  
Generally, NPS were legally defined by the European Union (EU), as a “new narcotic 
drug or psychotropic drug in pure form or in a preparation, that is not scheduled under 
the Single Convention on Narcotic Drugs of 1961 or the Convention on Psychotropic 
Substances of 1971, but which may pose a public health threat comparable to that 
posed by substances listed in those conventions” (Council of the European Union 
decision 2005/387/JHA). Thus, NPS are compounds with similar effects to drugs that 
are internationally controlled. NPS are not only one class of substances; they can be 
classified in different categories, depending on the illicit drug they refer to. The group 
of synthetic cannabinoids (e.g. MAM-2201) mimic the effects of Δ9-
tetrahydrocannabinol (THC), the active ingredient in cannabis plants (cannabis sativa), 
and bind to the cannabinoid receptor type 1 (CB1). The highly potent compounds, 
mainly more potent than THC itself, were often sprayed on various herbal mixtures and 
sold under brand names like “Spice” or “K2”. The synthetic cathinones (e.g. 
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mephedrone) should mimic the effects of cathinone, which is present in the leaves of 
the khat plant (catha edulis) as active ingredient, and are (mis-)used as stimulants. 
The phenethylamines cover a wide range of compounds, which contain the 
phenethylamine backbone, e.g. amphetamine-type stimulants, which should act like 
amphetamine, methamphetamine or 3,4-methylenedioxymethamphetamine (MDMA) 
or compounds of the hallucinogenic 2C-series, which have similar effects to mescaline. 
Other categories defined by the European Monitoring Centre for Drugs and Drug 
Addition (EMCDDA) are e.g. piperazines (stimulating drugs) and tryptamines 
(hallucinogenics). Compounds that did not fit into any of the above mentioned drug 
families are summarized in the category of “other drugs”. This class can respectively 
contain plant-based compounds or synthetic cocaine derivatives such as kratom or 
dimethocaine. 
 
 
Fig. 1 Number of identified NPS reported to the EU EWS from 2009 to 2014  
(data according to refs. [5-12]) 
To fight this phenomenon or to keep track of the compounds that flood the market, 
there are several regional, national, and international drug monitoring systems, 
executed for example by the EMCDDA or the United Nation Organization on Drugs 
and Crime (UNODC). Every year more and more NPS entered the market and were 
notified by these Early Warning systems (EWS). The results of these notifications can 
be found, amongst other information, in the annual reports of the EMCDDA or the 
UNODC. In 2014 in Europe, 101 new NPS were reported by member states of the EU. 
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From these, 31 have been synthetic cathinones, 30 synthetic cannabinoids, and 9 
phenethylamines. In 2013, 81 new NPS were reported amongst them 29 synthetic 
cannabinoids, 13 substituted phenethylamines, and 7 synthetic cathinones. In addition, 
651 websites offering “legal highs” were identified. All over the world, 97 new NPS 
have been reported in 2013, whereas 48 have been synthetic cannabinoids, 16 
phenethylamines and 8 synthetic cathinones [1, 2, 6-17]. 
Figure 1 shows the number of identified NPS reported to the EU EWS from 2009 to 
2014, it can be seen that the number highly increased in the last six years.  
 
 
Fig. 2 Number and main groups of newly identified NPS reported to the EU EWS from 2009-2014 
(data according to refs. [5-12])  
Figure 2 shows the distribution of the newly identified NPS into the different classes. 
The most predominant groups in the last six years were the synthetic cannabinoids, 
the phenethylamines, and the synthetic cathinones.  
The overall distribution of notified NPS in the last six years is shown in Figure 3. 
Synthetic cannabinoids represented 35% of the notified NPS, whereas 
phenethylamines accounted for 14% and synthetic cathinones for 19%.  
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As the data show, phenethylamines are the third most increasing group in the last six 
years. Therefore, they should be studied regarding their pharmacological and 
pharmacokinetic properties, such as receptor affinity, enzyme inhibitory potential, and 
metabolism including (toxicological) detection in biosamples.  
  
Fig. 3 Distribution of identified NPS reported to the EU EWS from 2009-2014 
(data according to refs. [5-12]) 
Well-known illicit phenethylamine representatives are, as already mentioned, 
amphetamine, methamphetamine, and MDMA. NPS derived from these compounds 
contain the phenylisopropylamine backbone (e.g. 4-MA). Also bioisosteric substitution 
of the benzene ring was observed, e.g. by a thiophene ring (methiopropamine, 2-MPA). 
Amphetamine-derived NPS mimic the dopaminergic, noradrenergic, and serotonergic 
effects of their illicit companions and thus have psychoactive, stimulating effects.  
1.1.2 Pharmacology and Toxicology of Amphetamine-derived NPS 
As already described above, amphetamine-derived NPS are intended to mimic the 
effects of amphetamines and methamphetamines. Both are indirect sympathomimetics 
and the mechanism of action is based on a reuptake transporter inhibition rather than 
to a direct release of these monoamines [18]. Amphetamine derivatives act as 
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competitive substrates of dopamine (DAT), noradrenaline (NAT), and serotonin 
(SERT) reuptake transporters and thus inhibit the reuptake of dopamine (DA), 
noradrenalin (NA), and serotonin (5-HT) in different potencies [19]. In addition, this 
leads to the reverse transport of monoamines in the synaptic cleft, resulting in higher 
concentrations of the respective monoamines. Thereby, DA produces the desired 
euphoric effects, whereas NA is responsible for the central stimulation. MDMA affects 
more the 5-HT release in contrast to amphetamine and methamphetamine, which have 
higher effects on DA and NA release. Therefore, the described effects when (mis-) 
using MDMA include, beside euphoria, stimulation, and increased wakefulness, also 
an increased sociability, extraversion, sharpened sensory perception, and an 
increased sense of closeness to other people. These MDMA effects were also 
summarized under the term of “empathogen" or “entactogen” [20].  
Unfortunately, the pharmacological effects of most new designer drugs were not 
studied, as they were not used as medication. The only – non-scientific – source of 
information on the respective effects of new drugs of abuse (DoA) are trip reports of 
drug users, published e.g. on www.bluelight.org or www.land-der-traeume.de. These 
trip reports are very popular among drug users and serve as information source and 
platform for the exchange of information. For example, information on dosing or routes 
of administration can be found as well as discussions about the general potential of a 
particular NPS. However, these reports have to be interpreted with caution since the 
users cannot be sure about what they consumed due to the variable content of internet 
purchased products [21, 22]. Unfortunately, only few scientific information is available 
on the pharmacology of amphetamine-derived NPS. For more details, see Chapters 
2.1 – 2.5.  
There are also no data available on the toxicity of these compounds. Nevertheless, 
several case reports were published after ingestion of NPS [23-29]. In general, side 
effects described in these case reports were nausea, insomnia, hyperthermia, and 
cardiovascular symptoms, all typical for amphetamine-type stimulants. After intake of 
5-APB and 6-APB, respectively, hallucinations or acute psychosis have been 
described indicating more serotonergic effects. Unfortunately, due to poly-drug use in 
most of the described cases, it is not sure, which compound is responsible for the 
observed effects. Poly-drug use is always a health threat as no one could estimate the 
additive effects of DoA mixtures.  
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As already mentioned, there is only little information about the pharmacology and 
toxicology of new psychoactive substances. Indeed, the effects of NPS could be 
estimated through known compounds with similar structures. The studies of Iversen et 
al. [30], who tested several NPS for their in vitro ability to inhibit NAT, DAT, and SERT, 
are of great importance when trying to estimate the effects and health threat of NPS. 
Green and Nutt also require that pharmacology studies should be in the center of 
clinical studies even for NPS [31]. Nevertheless, there is need of more studies, such 
as long-term toxicity and the risk of combining several NPS because of enzyme 
inhibition potentials.  
1.1.3 General Information and Structures of the Tested Stimulants 
1.1.3.1 Methiopropamine 
2-Methiopropamine, 1-(thiophen-2-yl)-2-methylaminopropane (2-MPA), is a thiophene 
analogue of methamphetamine, where the benzene ring was bioisosterically 
substituted. Therefore, it is not a classic phenethylamine. Figure 4 shows the chemical 
structures of 2-MPA compared to amphetamine and methamphetamine. Blicke and 
Burkhalter first synthesized 2-MPA in 1942 and described its pharmacological 
properties (e.g. pressor activity) being similar to the corresponding benzene analogues 
[32]. 
 
 
Fig. 4 Structure of amphetamine, 2-MPA, and methamphetamine 
In 2010, it achieved attention as “legal high” when it appeared on several websites 
offering NPS. Iversen et al. [30] showed that 2-MPA acts as noradrenaline (NA) and 
dopamine (DA) reuptake inhibitor, less potent than amphetamine but with similar 
potencies. This is in accordance to users’ reports on internet forums (e.g. 
www.bluelight.org and www.land-der-traeume.de) describing as desired effects 
stimulation and mild euphoria and as adverse effects hypertension, tachycardia, and 
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increased sweating. Several seizures and the occurrence in forensic case work lead 
to controlling of the compound in some European countries, e.g. Switzerland (2012) 
and Germany (2013). Nevertheless, it is still available on the internet and continuing 
discussions on drug users’ forums showing its ongoing relevance. For more details 
about 2-MPA, see Chapter 2.1. So far, no data were available on its metabolism or 
detectability in biosamples. Therefore, studies on its metabolism and the toxicological 
detectability in biosamples are of great interest. 
1.1.3.2 2-, 3-, and 4-Methyl-Amphetamine 
4-Methyl-amphetamine (1-(4-methylphenyl)propane-2-amine, 4-MA), the para-methyl 
analogue of amphetamine, was developed in the 1950s when it was studied as appetite 
suppressant under the trade name Aptrol®, but was never sold as such. It reachieved 
importance in 2010 when it was found in a seized powder sample in Germany labelled 
as amphetamine [33]. The EMCDDA joint report on 4-MA also showed that 4-MA was 
sold on the illicit market as amphetamine in several other countries [26]. In addition, 
several severe poisonings and fatalities most probably due to overdosing have been 
reported after use of contaminated “speed” [26, 29]. 
 
  
Fig. 5 Structures of 2-MA, 3-MA, and 4-MA 
The chemical structures of 4-MA and its 2-methyl (2-MA) and 3-methyl isomers (3-MA) 
are depicted in Figure 5. For more details, see Chapter 2.2. In March 2013, the EU 
Council decided an EU-wide control of 4-MA based on the EMCDDA joint report. 
However, the other isomers, 2-MA and 3-MA, are uncontrolled, therefore differentiation 
of the three isomers after ingestion is an important analytical task in forensic toxicology. 
Until now, no data were available on the metabolism or the selective detectability in 
biological samples and only 4-MA was integrated either in a LC-TOF screening in 
whole blood or in an LC-MS/MS screening in oral fluid [34, 35]. Therefore, studies 
should be performed on the metabolism and detectability of all of these compounds. 
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1.1.3.3 Camfetamine 
Camfetamine (N-methyl-3-phenyl-norbornan-2-amine, CFA) is not substituted at the 
ring system like the other tested compounds but at the alkyl chain. CFA has a 
phenethylamine backbone and belongs to the group of amphetamine-derived NPS. 
CFA is structurally related to fencamfamine (N-ethyl-3-phenyl-norbornan-2-amine; 
FCF), which is the corresponding N-ethyl analogue and both compounds can be seen 
as camphor derivatives with a norbornane ring system (Figure 6).  
 
 
Fig. 6 Structures of camfetamine (CFA) and fencamfamine (FCF) 
No data are available on CFA, but FCF was developed in the 1960s as appetite 
suppressant and was tested for its pharmacological effects [36-43]. For more details 
about CFA, see Chapter 2.3. CFA is, in contrast to FCF, not scheduled in Germany, 
therefore it is quite probable that it is still used as “legal high”. Cinosi et al. also 
supposed ongoing use of CFA [44]. For toxicological detection of CFA metabolism 
studies should be performed. 
1.1.3.4 5-APB, 6-APB, 5-MAPB and 6-MAPB (“Benzofuries”) 
“Benzofury” is a trade name related to 6-(2-aminopropyl)benzofuran (6-APB), but is 
also used for several benzofuran-containing compounds. 6-APB, its 5-isomer 5-APB 
(5-(2-aminopropyl)benzofuran) and their N-methyl derivatives 5-MAPB (N-methyl-5-(2-
aminopropyl)benzofuran) and 6-MAPB (N-methyl-6-(2-aminopropyl)benzofuran) are 
benzofuran analogues of amphetamine and methamphetamine by “adding” a furan ring 
to the benzene ring. Considering the benzofuran ring, they can also be seen as 
analogues of 3,4-methylenedioxy-amphetamine (MDA) and 3,4-methylenedioxy-
methamphetamine (MDMA), where one oxygen (-O-) in the methylenedioxy ring was 
replaced by methine (-CH=). Due to the structural similarities, it is not a surprise that 
the reported effects on drug users’ forums are also more MDMA- and MDA-like. MDA 
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is the N-demethyl metabolite of MDMA, but is also misused as stimulant and thus 
controlled in Germany. Figure 7 shows the chemical structures of the tested 
benzofuran-containing compounds, MDA and MDMA.  
Since 2010, these compounds appear consecutively on the internet and users started 
to discuss their effects. More details can be found in Chapter 2.4 and 2.5.  
 
 
Fig. 7 Structures of 5-APB, 6-APB, MDA, MDMA, 5-MAPB and 6-MAPB 
In Germany, 5-APB and 6-APB were controlled since 2013, but the corresponding N-
methyl derivatives are not. A few data on analytical characterization have been 
published by Casale et al. and Stanczuk et al. but only applied on internet purchased 
products [45, 46]. They separated the positional isomers of APB with GC-MS with or 
without derivatization. Data on analytical separation in biosamples are not available so 
far, and the metabolism of these compounds has not been studied yet. However, this 
is of great interest as these compounds are still discussed and sold on the internet and 
several case reports have been published showing that these compounds are also a 
possible public health threat [23, 25, 28, 29]. Another interesting question could be if 
the position of the oxygen in the furan ring makes any difference in metabolism caused 
by different fitting in the active center of involved enzymes. 
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1.1.4 Metabolism of Amphetamine-derived NPS 
In general, metabolic reactions should facilitate the (renal) excretion of lipophilic 
endogenous or exogenous compounds. Therefore, several metabolizing enzyme 
systems catalyze different reactions resulting in metabolites that are either 
pharmacologically and toxicologically active or inactive. The metabolic reactions can 
be divided into different phases. Phase I metabolizing enzymes create nucleophilic or 
electrophilic compounds, e.g. by oxidative or reductive reactions. This step is also 
called functionalization. An important phase I enzyme system are the cytochrome P450 
monooxigenases (CYP), which are not selective and transform several different 
compound classes [47]. These activated compounds were then conjugated e.g. with 
glucuronic acid, sulfuric acid (nucleophilic compounds) or with glutathione (electrophilic 
compounds) by the corresponding phase II metabolizing enzymes. The main metabolic 
steps observed for amphetamine- or methamphetamine-derived compounds are 
aromatic hydroxylation, aliphatic hydroxylation, N-demethylation, and oxidative 
deamination [48, 49]. MDMA-derived compounds show O-demethylenation to 
dihydroxy derivatives followed by methylation of one hydroxy group, N-demethylation, 
and oxidative deamination [50]. The knowledge of the metabolic fate of compounds is 
important for assessing the risk of pharmacokinetic interactions and pharmacogenomic 
variations.  
Toxicological detection in forensic and clinical cases is often performed with 
metabolite-based screening-approaches and for the development of such screening 
approaches metabolism studies should be executed [51-53]. As already mentioned 
above, for NPS or other DoA, such studies are not performed before marketing in 
contrast to drugs used in medicine. To test for the metabolic fate of drugs, different 
approaches are possible. In vitro assays using human recombinant enzymes, liver 
preparations or hepatocytes can be used as well as animal models, e.g. with rats 
whose qualitative metabolic profiles turned out to be similar to that of humans [54-56]. 
Combining rat animal studies with human liver microsomes incubations allowed a 
good, at least qualitative prediction of human metabolism [57-69]. 
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1.1.5 Involvement of CYP Isoenzymes in the Metabolism 
As already mentioned above, one of the main metabolizing enzyme systems are the 
CYP isoenzymes. These isoenzymes were not only involved in the metabolism of NPS 
or DoA, but in the metabolism of several endogenous and exogenous compounds [47]. 
To estimate or predict the risk of drug-drug interactions and pharmacogenomics 
variations, an initial CYP activity screening might help. The ten most abundant CYP 
isoenzymes are tested for their involvement in the main metabolic steps. The results 
can help to give a preliminary hint of potential drug-drug interactions with medicaments 
or other DoA. However, the real distribution of the respective isoenzymes in the liver 
and affinities of a substrate to different isoenzymes is not considered. Therefore, kinetic 
studies should be performed if reference standards of the metabolites, which are 
needed for the quantification, are available [70-74]. Unfortunately, especially for new 
DoA, such reference standards are rarely commercially available. One possibility to 
perform kinetic studies without a reference standard is the substrate depletion 
approach [75, 76]. However, this approach only allows the determination of Km 
(Michaelis-Menten constant) and not Vmax values [74-76]. Once, Vmax and Km values 
are determined, calculation of the real contribution of the particular enzyme to hepatic 
excretion is possible and thus estimation of the risk of drug-drug interactions.  
1.1.6 Analytical Challenge and Toxicological Detectability 
As one could imagine, the rapid increase of NPS on the market also challenges the 
respective forensic or clinical laboratories. It is like the race between the hare and the 
hedgehog, once a new reference standard was synthesized or a new method was 
validated, several other compounds appear on the market and the competition restarts 
[77]. For identification of pure compounds in seized material, some approaches have 
been published [21, 45, 77-81].  
Nevertheless, toxicological detection in biosamples, such as blood or urine, is even 
more challenging because of the small detection window in blood and the possible 
absence of the parent compounds in urine samples due to extensive metabolism. Two 
reviews have been published recently, focusing on the analytical challenge covering 
NPS [77, 82]. Peters summarized the method developments in urinalysis that were 
published since 2008 and summarizes the different techniques regarding formation of 
the metabolites, sample preparation, or analytical detection, including various 
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instrumentations (e.g. GC-MS, LC-MS) and detection modes (e.g. targeted or general 
unknown). Especially, when using the targeted or the general unknown mode in 
urinalysis, knowledge of the excretion products or the metabolites of a respective 
compound is of great importance. Therefore, metabolism studies should be performed 
and a metabolite-based library should be created and used for identification as 
described previously [52, 53, 83, 84]. In this work, the detectability studies were 
performed in rat urine after application of a low dose, which was calculated according 
to the reported single doses on drug forums. If human urine samples were available, 
those have been additionally investigated even if the ingested doses were not known, 
for comparison of the metabolic patterns between humans and rat.  
1.1.7 Isomer Differentiation 
Some of the compounds were available as different positional isomers, e.g. the three 
methyl-amphetamines and the benzofurans. As some of these compounds were 
controlled substances in Germany (4-MA, 5-APB and 6-APB), isomer differentiation 
could be necessary.  
For isomer differentiation, solid phase extraction was used followed by derivatization 
via heptafluorobutyrylation according to a published procedure for plasma by Peters et 
al. [85]. For the results of the separation studies on the three methyl-amphetamine 
isomers or the benzofuries, see chapter 2.2 or 2.5, respectively. 
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1.2 Aims of the dissertation and resulting publications 
 
So far, no studies were available on the metabolism and toxicological detectability of 
the above-mentioned compounds. Therefore, the aims of this dissertation and the 
resulting publications are given below: 
 
 Identification of the phase I and II metabolites in rat (and human) using GC-
MS and LC techniques coupled to either low or high resolution mass 
spectrometry (LC-MSn or LC-HR-MSn) 
(Chapters 2.1 – 2.5) 
 Confirmation of the phase I metabolites in human liver microsomes 
preparations and identification of the involved cytochrome P450 (CYP) 
isoenzymes 
(Chapters 2.1 – 2.5) 
 Investigation of the detectability in urine within standard urine screening 
approaches (SUSA) using GC-MS and LC-MSn 
(Chapters 2.1 – 2.5) 
 Determination of human plasma concentrations after ingestion of 5-MAPB 
(Chapter 2.4) 
 Quantitative in vitro enzyme kinetics of 5-MAPB N-demethylation and 
determination of the in vivo contribution 
(Chapter 2.4) 
 Separation of the methyl-amphetamine isomers or the benzofuran-containing 
isomers in urine using GC-MS 
(Chapters 2.2 and 2.5) 
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2 PUBLICATION OF THE RESULTS 
The results of the studies were published in the following papers: 
2.1 2-Methiopropamine, a thiophene analogue of methamphetamine: studies 
on its metabolism and detectability in the rat and human using GC-MS 
and LC-(HR)-MS techniques [57] 
(DOI: 10.1007/s00216-013-6741-4) 
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2.2 Studies on the metabolism and the detectability of 4-methyl-amphetamine 
and its isomers 2-methyl-amphetamine and 3-methyl-amphetamine in rat 
urine using GC-MS and LC-(high-resolution)-MSn [86] 
(DOI: 10.1007/s00216-013-7595-5)
19 
2.3 GC-MS and LC-(high-resolution)-MSn studies on the metabolic fate and 
detectability of camfetamine in rat urine [87] 
(DOI: 10.1007/s00216-014-7796-6)
21 
2.4 Benzofuran analogues of amphetamine and methamphetamine: studies 
on the metabolism and toxicological analysis of 5-APB and 5-MAPB in 
urine and plasma using GC-MS and LC-(HR)-MSn techniques [58] 
(DOI: 10.1007/s00216-014-8360-0) 
23 
2.5 Metabolic fate, mass spectral fragmentation, detectability, and 
differentiation in urine of the benzofuran designer drugs 6-APB and 6-
MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MSn 
techniques [88] 
(DOI: 10.1007/s00216-015-8552-2)
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3 CONCLUSIONS  
The presented studies provide systematic data on the metabolism and toxicological 
detection of several amphetamine-derived compounds belonging to the 
phenethylamine group of new psychoactive substances. They were performed using 
rat urine, human liver preparations and, if available, human urine. These data show 
that the methamphetamine-derived compounds, 2-MPA, 5-MAPB, and 6-MAPB, were 
only metabolized to a minor extent. N-Demethylation was the predominant metabolic 
step, resulting in the corresponding nor metabolites. These nor metabolites were 
beside the parent compounds the second most important target for urinalysis. For 2-
MPA and 5-MAPB, these results could also be confirmed in human urine. The CYP 
isoenzymes involved in the N-demethylation were more or less the same for each 
compound, namely CYP2B6, CYP2C19, CYP2D6, and CYP3A4. The other two 
benzofuran-containing compounds, 5-APB and 6-APB, were metabolized even less 
than the methamphetamine-derived compounds. The main excretion products and 
thus the targets for urinalysis were 5-APB and 6-APB themselves. In the metabolism 
studies, at least some metabolic steps could be detected, such as ring cleavage, but 
only to a minor extent and only in the high dose rat urine. Evaluation of the initial CYP 
activity screening was also not possible due to small formation rates or multiple step 
reactions (e.g. ring cleavage).  
The methyl-amphetamine isomers 2-MA, 3-MA, and 4-MA showed different 
degradation. Although they are amphetamine derivatives, the main excretion products 
in urine were the hydroxy-aryl metabolites beside the parent compounds. These 
isomers also show that the position of the methyl group in the aromatic ring affects the 
metabolism, as 2-MA was metabolized more extensive than the other isomers. As 
already mentioned, aromatic hydroxylation was the main metabolic step observed for 
the methyl-amphetamine isomers and this step was catalyzed only by CYP2D6, which 
is accordance to published results about amphetamine [89]. For CFA, which was the 
only investigated compound with the variation in the side chain, the observed 
metabolism was very extensive. This resulted in the excretion of several different 
metabolites even in the low dose rat urine, namely, hydroxy-aryl, nor-hydroxy-aryl, and 
nor CFA. CFA itself was excreted only in a minor concentration. Therefore, the main 
targets for urinalysis were the hydroxy-metabolites. The CYP isoenzymes involved in 
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the aromatic hydroxylation were CYP2C19 and CYP2D6 and those involved in the N-
demethylation were CYP2B6, CYP2C19, CYP2D6, and CYP3A4.  
In summary, it can be seen, that the N-demethylations for all tested compounds were 
more or less catalyzed by the same CYP isoenzymes, namely CYP2B6, CYP2C19, 
CYP2D6, and CYP3A4. And also the aromatic hydroxylation was mainly catalyzed by 
CYP2D6, even if for CFA also CYP2C19 was additionally observed as catalyzing 
enzyme.  
Concerning phase II metabolism, for all tested compounds, glucuronidation and 
sulfation of the corresponding functionalized metabolites could be observed, even if 
these steps play only a minor role, with the exception of CFA, 2-MA, and 3-MA, where 
the hydroxy-aryl glucuronides could also be detected in the LC-MSn standard urine 
screening approaches (SUSA) after the low dose. Hydroxy-aryl CFA glucuronide was 
even a main target in the low dose rat urine.  
Separation of the methyl-amphetamine isomers or the benzofuran isomers has been 
performed with an additional work-up because they were not distinguishable within the 
used GC-MS or LC-MSn SUSAs. The sample preparation consisted of a solid-phase 
extraction (SPE) and a following heptafluorobutyrylation according to published 
procedures for plasma [85]. Separation was then performed using GC-MS with longer 
HP5 columns compared to routine conditions and special temperature gradients.  
In the case of 5-MAPB, six human samples have been send to the laboratory for 
toxicological diagnostic reasons after ingestion of 5-MAPB. Therefore, quantification of 
the plasma concentrations of 5-MAPB and its main metabolite 5-APB was possible. 
The determined concentrations ranged between 5 and 124 µg/L for 5-MAPB and from 
1 to 38 µg/L for 5-APB. Considering similar doses for MDMA and 5-MAPB, as 
described on drug users’ internet forums, these concentrations are comparable to 
published data for MDMA (1–514 μg/L) and MDA (1–67 μg/L) [50, 90]. 
The results presented here show that metabolism studies on new psychoactive 
substances are of great necessity. The targets for urinalysis are not always the parent 
compounds; depending on the extent of metabolism the unchanged drug is only 
excreted in a minor concentration. Therefore, the metabolic fate of such compounds 
should be tested systematically. The information obtained from these studies can help 
to create a library-based approach for the identification of NPS in urine. With the results 
from the studies presented here, the intake of each tested compound could be proved 
using the established SUSAs.  
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5 ABBREVIATIONS 
2-MA 2-methyl-amphetamine 
2-MPA 2-methiopropamine 
3-MA 3-methyl-amphetamine 
4-MA 4-methyl-amphetamine 
5-APB 5-aminopropylbenzofuran 
5-HT serotonin 
5-MAPB N-methyl-5-aminopropylbenzofuran 
6-APB 6-aminopropylbenzofuran 
6-MAPB N-methyl-6-aminopropylbenzofuran 
CB1 cannabinoid receptor type 1  
CFA camfetamine 
CYP cytochrome P450 
DA dopamine 
DAT dopamine transporter 
DoA drugs of abuse 
EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
EU European Union 
EWS Early Warning System 
FCF fencamfamine 
GC gas chromatography 
HLM human liver microsomes 
HR high resolution 
LC liquid chromatography 
MDA 3,4-methylenedioxyamphetamine 
MDMA 3,4-methylenedioxymethamphetamine 
MS mass spectrometry 
NA noradrenalin  
NAT noradrenalin transporter 
NPS new psychoactive substances 
SERT serotonin transporter 
SPE solid-phase extraction 
SUSA standard urine screening approach 
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THC Δ9-tetrahydrocannabinol 
TOF time-of-flight 
UN United Nations 
UNODC United Nations Office on Drugs and Crime 
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6 SUMMARY 
The number of new psychoactive substances identified each year by the EMCDDA is 
increasing rapidly, as in 2014, 101 new compounds have been identified. One 
important structural group of NPS are the phenethylamines. In the presented studies, 
the metabolic fate and the toxicological detection of different amphetamine-derived 
compounds belonging to the phenethylamine group of NPS have been investigated. 
Using GC-MS and/or LC-High-Resolution-MSn, the main phase I metabolic step 
observed for the compounds containing the methamphetamine backbone, such as 
2-MPA, 5-MAPB, and 6-MAPB, was N-demethylation, whereas for the three methyl-
amphetamine isomers and CFA aromatic hydroxylation was the predominant step. 
5-APB and 6-APB were metabolized only to a minor extent, resulting in the unchanged 
drug being the main target for urinalysis. The isoenzymes mainly involved in the 
N-demethylation steps were CYP2B6, CYP2C19, CYP2D6, and CYP3A4, whereas the 
aromatic hydroxylations were catalyzed by CYP2D6 and CYP2C19. The intake of each 
tested compound could be proved within the established SUSAs, either with the 
unchanged drugs or the nor metabolites being the main targets in urine, or in the case 
of CFA and the three MAs, the hydroxy-aryl metabolites. Separation of isomers was 
successfully accomplished with an additional work-up, including 
heptafluorobutyrylation. For 5-MAPB, plasma concentrations determined in authentic 
cases were in the same range as published for MDMA. 
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7 ZUSAMMENFASSUNG 
Die Anzahl neuer psychoaktiver Substanzen, die jedes Jahr von der EMCDDA 
identifiziert wird, steigt stetig an. Alleine 2014, wurden 101 neue Substanzen 
identifiziert. Die Phenethylamine stellen dabei eine wichtige Gruppe dar, deshalb 
wurde im Rahmen dieser Dissertation der Metabolismus und die Nachweisbarkeit von 
verschiedenen Phenethylamin-Abkömmlingen mittels GC-MS- und LC-(HR)-MSn-
Verfahren untersucht. Für Substanzen, mit einer Methamphetamin-verwandten 
Struktur, wie 2-MPA, 5-MAPB und 6-MAPB, war der nachgewiesene 
Hauptstoffwechselschritt die N-Demethylierung, während es für die drei Isomere des 
Methyl-Amphetamins und CFA, die aromatische Hydroxylierung war. 5-APB und 
6-APB wurden insgesamt nur wenig verstoffwechselt, was dazu führt, dass 
hauptsächlich der unveränderte Stoff im Urin nachgewiesen wurde. CYP2B6, 
CYP2C19, CYP2D6 und CYP3A4 waren an der N-Demethylierung beziehungsweise 
CYP2D6 und CYP2C19 an der aromatischen Hydroxylierung beteiligt. Eine Einnahme 
der untersuchten Substanzen konnte im Urin nachgewiesen werden mithilfe der im 
Labor durchgeführten Standard Urinscreening-Verfahren. Der Fokus für die 
Nachweisbarkeit lag dabei entweder auf den unveränderten Substanzen, und den Nor-
Metaboliten, oder im Fall von CFA und den Methyl-Amphetaminen auf den Hydroxy-
Aryl-Metaboliten. Eine Isomeren-Trennung wurde erfolgreich durchgeführt. 5-MAPB-
Plasmakonzentrationen, die in authentischen Fällen bestimmt wurden, waren 
vergleichbar mit bekannten MDMA-Konzentrationen. 
 
